Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

 Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

Shots:

  • Sun Pharma has filed manufacturing and marketing authorization of Tildrakizumab to the PMDA for moderate-to-severe psoriasis and psoriatic arthritis in Japan
  • Additionally, Sun Pharma has acquired Pola Pharma and will leverage Pola’s strong presence in the dermatology to commercialize Tildrakizumab in Japan which will expand Sun Pharma’s global franchise and robust its dermatology pipeline
  • Tildrakizumab-asmn is an lgG1/k mAb targeting p19 subunit of IL-23, inhibiting its interaction with IL-23, resulting in inhibition of release of pro-inflammatory cytokines and chemokines and is an approved therapy in the US & Australia as Ilumya and in Europe as Ilumetri

Click here to­ read full press release/article | Ref: Sun Pharma | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post